Member Info for Candid

I think the scoping study will show that the project is very robust. Once PGM prices rise (just a matter of time) this will be an outstanding mine opportunity and surely it will get some of the majors looking to JV.

For a £12m market cap this looks a good entry point.

SVM asset management were one of the original funds who invested at the IPO in 2019 at a 100p placing price, most of these funds have sold up now including Black Rock, Fidelity. They have taken their tax losses and moved on according with their ever changing investment policies. I think it’s good they have mostly sold out as it was keeping a big downward pressure on the share price. Now we have more nimble investors like A. Bruce and the Swiss hedge fund who recognise the value & potential here at this level.

Looking at today’s late reported large volume trades, it looks like sells. Depending who’s been selling in the last couple of weeks we might see more or this may be it. (From the volume it looks like one of the top 3 holders).

Good updates and LBE is very well positioned, hopefully 2024 will deliver some solid progress in Norway and Malaysia. Agree that market cap is too low, valuation should be higher,

I believe recent share price weakness has been a a result of a seller putting downward pressure in a tightly held float. Around 2.6m shares were sold last week so perhaps the overhang has been cleared if they are done, we’ll prob see an RNS to notify a change in holdings.

Making good progress on contract wins but the shareprice is on it’s lows. I think the market is still not convinced about the revenue and profits, the annual results are due any day now and will highlight key financials. Once significant contracts are won and ongoing revenue is established this will make a solid business, but we may not be there just yet. Not holding but waiting to see how things develop.

Not sure what I’m missing on this one, Panton is a significant and high grade resource in a safe mining jurisdiction, processing flow ticked and it compares very well against its peers in Australia such as Chalice.

Scoping study out this quarter and everything to play for.

If it’s ongoing funding that’s keeping it down then a JV is a very likely possibility.

Well done Atlantic, that’s a fantastic result.

The news just keeps getting better here for XF-73, so glad they are still expanding the value of this before any major pharma players offer deals and partnerships.

Demonstrate the massive scope & potential - that will get you into the best negotiation position, we know the major US players want to commercialise this.

I thought YCA needed to be in positive NAV before they could raise capital, maybe this was just triggered last week for a short time. Anyway looks to be a great bit of business to lock in the KAP option at $65.50, spot market is already $72 as I write. Who knows where the U308 price discovery will go in the weeks & months ahead.

Ironknut, the NHS has been collaborating with this test since the start including trials so are well in the loop here already.

They need it and I believe some NHS trusts will be busy promoting it.

“The test was developed by Oxford Biodynamics in collaboration with UEA, Imperial College London and Imperial College NHS Trust”

Am very impressed with this management team now: US & UK launch well ahead of schedule, excellent marketing, dedicated laboratories in the US and UK, partnerships with top academic institutions.

Can this new PSE test shake up and improve the global PSA testing protocol? (which needs significant improvement anyway)

If so the commercial opportunity is huge.

Although a big find has not come in this time the fact that the main risk (reservoir quality) has turned out positive is a good opportunity to assess other targets in this licence and LBE could still celebrate a commercial discovery on the next drill.

“the license contains numerous other prospects which have been derisked by the presence of gas in good quality reservoir in the Velocette well," Longboat JAPEX Norge said.

"The remaining prospectivity has significant size potential in multiple structures”

Share price is still very cheap at these levels IMO.

ID78, yes not everyone offers this, although it’s listed in London it’s classed as an ‘international share’ and traded in US dollars. I use Interactive Investor platform, they are good for international shares. Maybe call up HL as they might do it over the phone.

Knew this would be huge, it’s a world class project that will likely attract a major miner into a JV or will involve a direct sale.

What’s important is that vanadium and sulphate of potash are the biggest value drivers of the project NOT uranium.

There is the optionality to go ahead without extracting the uranium and hence the existing uranium ban is not a blocker any more. (While the chances of getting the uranium ban overturned are looking quite good and the government has been making the right noises it’s not totally dependent on this outcome)

Of course the project economics will be even more robust with the full suite & the byproducts

The Project's major value drivers are vanadium and the key agricultural by-product sulphate of potash (SOP), with a mixed sulphide precipitate of nickel, zinc, and molybdenum proposed to be produced. Uranium is present in the polymetallic resource, like many deposits in Sweden, and while it can add to the Project's economic value there exists at present a ban on the mining of uranium in Sweden. The Scoping Study outlines an option for a treatment and stabilisation plan that would treat the uranium into an inert safe waste product for long-term disposal or with approval from the government and community recover it in the processing circuit for sale into the domestic and or European markets.

Added more today

23p was the May 2023 high shortly after the Japex deal was announced. This week LBE bounced directly off this level.

I’ve bookmarked the following from the Japex news release:

“Regarding this transaction, we expect to invest approximately 150 million USD over the course of the next three years at this moment, for the exploration, development, and the acquisition of new interests”

Quiet here now but as Q4 approaches OBD is set to deliver.

Insiders have added in significant volumes during the recent placing

After more than a year of sideways chop KAP look set to join the uranium rally. Compared to Cameco, KAP has seriously underperformed, just look at Cameco’s 5 year chart!

KAP is more leveraged to a rising uranium spot price and bigger, more profitable.

Good to see investments by new funds, this along with heavy insider purchases in the latest fundraising bodes very well.

Not sure if the Odey Fund will exit but even if they do it looks like new investors are more than willing to load up.

Some good movement today, Aura should do well in the current run. Sentiment is building strongly in the uranium sector and Aura coming off lows. Upcoming Scoping study is also a catalyst here.